- Home
- IDR vs AURA Comparison
IDR vs AURA Comparison
Compare IDR & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- AURA
- Stock Information
- Founded
- IDR 1996
- AURA 2007
- Country
- IDR United States
- AURA United States
- Employees
- IDR N/A
- AURA N/A
- Industry
- IDR Precious Metals
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- AURA Health Care
- Exchange
- IDR Nasdaq
- AURA Nasdaq
- Market Cap
- IDR 378.0M
- AURA 396.8M
- IPO Year
- IDR N/A
- AURA 2021
- Fundamental
- Price
- IDR $38.86
- AURA $5.76
- Analyst Decision
- IDR Strong Buy
- AURA Strong Buy
- Analyst Count
- IDR 1
- AURA 7
- Target Price
- IDR $17.50
- AURA $22.29
- AVG Volume (30 Days)
- IDR 599.2K
- AURA 283.0K
- Earning Date
- IDR 11-03-2025
- AURA 11-11-2025
- Dividend Yield
- IDR N/A
- AURA N/A
- EPS Growth
- IDR 57.55
- AURA N/A
- EPS
- IDR 0.64
- AURA N/A
- Revenue
- IDR $30,496,328.00
- AURA N/A
- Revenue This Year
- IDR $21.91
- AURA N/A
- Revenue Next Year
- IDR $5.47
- AURA N/A
- P/E Ratio
- IDR $59.65
- AURA N/A
- Revenue Growth
- IDR 59.64
- AURA N/A
- 52 Week Low
- IDR $9.67
- AURA $4.35
- 52 Week High
- IDR $41.92
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- IDR 72.70
- AURA 37.10
- Support Level
- IDR $32.30
- AURA $5.93
- Resistance Level
- IDR $35.47
- AURA $6.28
- Average True Range (ATR)
- IDR 2.57
- AURA 0.26
- MACD
- IDR 0.59
- AURA -0.02
- Stochastic Oscillator
- IDR 77.18
- AURA 5.22
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.